FBR Remains Positive on Genocea Biosciences (GNCA) Following ATLAS Update; Affirms at 'Outperform'

November 11, 2016 11:41 AM EST
Get Alerts GNCA Hot Sheet
Price: $3.77 -0.79%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade GNCA Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

FBR & Co. reaffirms Genocea Biosciences, Inc. (Nasdaq: GNCA) at Outperform with a price target of $17 after the presented new findings supporting the potential of ATLAS, the Company’s proprietary rapid antigen identification screening system, to identify clinically meaningful personalized neoantigens that could guide development of neoantigen vaccines.

The firm commented today, Recall, ATLAS is Genocea's proprietary rapid antigen identification screening system, engineered to recreate patient-specific T cell immune response ex vivo. The technology could potentially provide a way to distinguish between neoanigens that can stimulate productive immunity and identify those that are associated with the inhibitory responses. The data to be presented tomorrow is based on the analysis of neoantigens in one non-small cell lung cancer (NSCLC) patient, treated with pembrolizumab. In the study, performed in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), 103 of patient's unique tumor mutations were screened to determine the neoantigens that could potentially contribute to the anti-tumor immune response. Many of the identified neoantigens were excluded by the commonly used predictive computational algorithms.

We are looking forward to the additional details on these data, and believe that ATLAS could become a groundbreaking tool in creating personalized vaccines.

For an analyst ratings summary and ratings history on Genocea Biosciences click here. For more ratings news on Genocea Biosciences click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Add Your Comment